The following authors have disclosed the following relationships: Dr. Weycker receives study support from Amgen; Dr. Li, Mr. Barron, Dr. Morrow, Dr. Xu, Ms. Reiner, and Dr. Garcia hold stock from and are employees of Amgen. Drs. Wu and Ms. Mhatre have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Dr. Lyman has disclosed that he is a PI for an institutional research grant from Amgen.
Funding for this research was provided by Amgen Inc. to Policy Analysis Inc. (PAI).
See JNCCN.org for supplemental online content.
Smith TJ, Khatcheressian J, Lyman GH et al.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–3205.
Lyman GH, Michels SL, Reynolds MW et al.. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010;116:5555–5563.
Kuderer NM, Dale DC, Crawford J et al.. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258–2266.
Bonadonna G, Moliterni A, Zambetti M et al.. 30 years' follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005;330:217.
Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524–4531.
Crawford J, Becker PS, Armitage J et al.. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. Version 2, 2014. Available at: NCCN.org. Accessed June 8, 2015.
Chao C, Page J, Yang S et al.. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol 2014;25:1821–1829.
Chao C, Rodriguez R, Page J et al.. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis. Leuk Lymphoma 2015;56:72–79.
Lyman G, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 2014;90:190–199.
Chia V, Page J, Rodriguez R et al.. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. Breast Cancer Res Treat 2013;138:621–631.
Hosmer W, Malin J, Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 2011;19:333–341.
- Search Google Scholar
- Export Citation
. Hosmer W Malin J Wong M Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 2011; 19: 333– 341.
Lyman G, Kuderer N, Crawford J et al.. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011;117:1917–1927.
Lyman G, Morrison V, Dale D et al.. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069–2076.
Schnipper L, Smith T, Raghavan D et al.. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012;30:1715–1724.
Aapro MS, Bohlius J, Cameron DA et al.. 2010 update of EORTC 2011 guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8–32.
- Search Google Scholar
- Export Citation
. Aapro MS Bohlius J Cameron DA 2010 update of EORTC 2011 guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8– 32.
Kuderer N, Lyman G. Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst 2011;103:910–913.
Kuderer N, Culakova E, Poniewierski M et al.. Personalizing supportive care: a clinical prediction model for neutropenic complications in patients with early-stage breast cancer (ESBC) receiving intermediate risk cancer chemotherapy [abstract]. Cancer Res 2011;71:Abstract P5-20-03.
- Search Google Scholar
- Export Citation
. Kuderer N Culakova E Poniewierski M Personalizing supportive care: a clinical prediction model for neutropenic complications in patients with early-stage breast cancer (ESBC) receiving intermediate risk cancer chemotherapy [abstract]. Cancer Res 2011; 71: Abstract P5-20-03.
Lyman G, Culakova E, Poniewierski M et al.. Personalizing cancer supportive care: predicting neutropenic complications in patients receiving intermediate risk cancer chemotherapy [abstract]. Blood 2011;118:Abstract 1022.
Kuderer NM, Wolff AC. Enhancing therapeutic decision making when options abound: toxicities matter. J Clin Oncol 2014;32:1990–1993.
Weycker D, Li X, Edelsberg J et al.. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. Support Care Cancer 2014;22:3275–3285.
Weycker D, Sofrygin O, Seefeld K et al.. Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Serv Res 2013;13:60.
Weycker D, Edelsberg J, Kartashov A et al.. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. Chemotherapy 2012;58:8–18.
U.S. Department of Health & Human Services. Code of Federal Regulations. Title 45: Public Welfare. Part 46: Protection of Human Subjects. Available at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html. Accessed July 4, 2013.
Lyman GH, Kleiner JM. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. J Natl Compr Canc Netw 2007;5:217–228.
Crawford J. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia. Oncology (Williston Park) 2006;20(5 Suppl 4):22–28.
Davidoff A, Hurria A, Zuckerman I et al.. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol 2013;4:157–165.
Davidoff A, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2191–2197.
Salloum R, Smith T, Jensen G, Lafata JE. Using claims-based measures to predict performance status score in lung cancer patients. Cancer 2011;117:1038–1048.
Lyman GH, Dale DC, Legg JC et al.. Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? [Published online ahead of print March 23, 2015.] Cancer Med. doi: 10.1002/cam4.454.
Culakova E, Poniewierski MS, Crawford J et al.. Impact of comorbidities on length of stay and mortality in hospitalized patients with cancer and febrile neutropenia [abstract]. Blood 2014;124:Abstract 2601.
Dulisse B, Li X, Gayle JA et al.. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 2013;16:720–735.
Waters G, Corrigan P, Gatesman M, Smith T. Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. J Oncol Pract 2013;9:203–206.
Potosky A, Malin J, Kim B et al.. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst 2011;103:979–982.